GSK CEO and CFO Interviewed on Q2 2014 Results and Strategy Update

LONDON, July 23, 2014 /PRNewswire/ --

Global healthcare company GSK reports Q2 results reflecting a business that is facing currency headwinds, increased price competition and supply disruptions to its Consumer business. However its CEO Sir Andrew Witty points out that the company is very much in transition, citing progress in the development pipeline as reason to be confident about long-term prospects as well as the investments being made to drive long-term growth.

CFO Simon Dingemans adds that the company is reining back on share buybacks for the year, revising its guidance, and formally launching a process to sell £1bn worth of sales from its established products portfolio as the company seeks to create a better balanced business.  

The interviews and transcript are available now on http://video.merchantcantos.com/.

MerchantCantos produces in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email [email protected] or phone +44-207-936-1352.

SOURCE GlaxoSmithKline

Suggested Articles

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.

Eli Lilly and Boehringer's Jardiance fell short in a heart failure trial in patients with or without diabetes—a test AZ's rival Farxiga recently aced.